For the Inventor, By the Inventor

Enter assignee name

Cambridge, MA, United States of America

Ksq Therapeutics, Inc.

USPTO Granted Patents = 19

EPO Patents = 2

Trademarks = 3

Forward Citations = 27

Loading Chart...

Loading Chart...

17 inventors (with patents filed for the assignee):

Michael R Schlabach (15 out of 15 patents)

Micah Benson (11 out of 12 patents)

Gregory V Kryukov (11 out of 11 patents)

4. Jason J Merkin (11 out of 11 patents)

5. Solomon Martin Shenker (9 out of 9 patents)

6. Noah Jacob Tubo (9 out of 9 patents)

7. James Martin Kaberna, Ii (6 out of 6 patents)

8. Hanlan Liu (2 out of 6 patents)

9. Elsa Beyer Krall (2 out of 2 patents)

10. Jehrod Burnett Brenneman (2 out of 3 patents)

11. Andrew Alistair Wylie (2 out of 4 patents)

12. Giuseppe Lapadula (1 out of 5 patents)

13. Jeremy Clinton Wilt (1 out of 1 patent)

14. Friedrich Blatter (1 out of 1 patent)

15. Anja Fides Hohmann (1 out of 1 patent)

19 patents: Sort by Forward Citations

1. 12624040 - Compositions of substituted pyrazolopyrimidines and uses thereof (2026-05-12),

2. 12590312 - NR4A SUPER-REPRESSORS AND METHODS OF USE THEREOF (2026-03-31),

3. 12280111 - Gene-regulating compositions and methods for improved immunotherapy (2025-04-21),

4. 12188045 - Guide RNA combinations and methods of use (2025-01-07),

5. 12123021 - Gene-regulating compositions and methods for improved immunotherapy (2024-10-22),

6. 12084682 - Gene-regulating compositions and methods for improved immunotherapy (2024-09-10),

7. 11946163 - Methods for measuring and improving CRISPR reagent function (2024-04-02),

8. 11912987 - Methods for screening for cancer targets (2024-02-27),

9. 11787813 - Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (USP1) inhibitors (2023-10-17),

10. 11718624 - Solid state forms of substituted pyrazolopyrimidines and uses thereof (2023-08-08),

11. 11608500 - Gene-regulating compositions and methods for improved immunotherapy (2023-03-21),

12. 11485736 - Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (USP1) inhibitors (2022-11-01),

13. 11459544 - Gene-regulating compositions and methods for improved immunotherapy (2022-10-04),

14. 11421228 - Gene-regulating compositions and methods for improved immunotherapy (2022-08-23),

15. 11332713 - Gene-regulating compositions and methods for improved immunotherapy (2022-05-17),

Company Overview

Ksq Therapeutics, Inc. is a biotechnology company based in Cambridge, MA, specializing in the development of innovative therapies that harness the power of the immune system to treat various diseases. The company focuses on advancing its proprietary platform to discover and develop novel drug candidates, particularly in the fields of oncology and autoimmune disorders. Ksq Therapeutics aims to address unmet medical needs through its cutting-edge research and commitment to scientific excellence.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

19 Patents

#145 in Cambridge, MA

#1,049 in Massachusetts

#17,138 in US

#32,663 in the World

Cambridge, MA, United States of America

Ksq Therapeutics, Inc.

Forward Citations = 27

17 inventors:

Michael R Schlabach (15 out of 15 patents)

Micah Benson (11 out of 12 patents)

Gregory V Kryukov (11 out of 11 patents)

4. Jason J Merkin (11 out of 11 patents)

5. Solomon Martin Shenker (9 out of 9 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Ksq Therapeutics, Inc.. Retrieved from https://idiyas.com/company/ksq-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…